null

Anti-Human VEGF (Bevacizumab) - Fc Reduced Biotin Biosimilar (IVMB0503)

SKU:
IVMB0503
Antibody Type:
Biotinylated Biosimilar
Modifications:
Biotinylated
Applications:
IHC
SPR
FC
ELISA
Drug Development
Pharmacokinetics
Disease Area:
Angiogenesis
Disease Area:
Cancer
Disease Area:
Ocular Disorders
€819

Description

system_update_altDatasheetsystem_update_altMSDS
Product Name:Anti-Human VEGF (Bevacizumab) - Biotin
SKU:IVMB0503
Size:100 µg
Antibody Type:Biosimilar Recombinant Human Monoclonal Antibody
Clone:A4.6.1
Target:VEGF
Isotype:Human IgG1κ
Host Species:Human
Reactivity:Human
Applications:ELISA
Expression Host:HEK-293 Cells
FC Effector Activity:Muted
Synonyms:Vascular Endothelial Growth Factor; VEGF-A; VEGFA; Vascular Permeability Factor; VPF
Product Concentration:0.5 mg/ml
Immunogen:Recombinant human VEGF.
Applications and Recommended Usage:FC The suggested concentration for Adalimumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
ELISA
Antigen Distribution:VEGF is widely expressed in the thyroid, prostate, and various other tissues.
Formulation:This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Specificity:This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Bevacizumab. Bevacizumab recognizes both native and reduced human VEGF (isoform 165). This product is for research use only.
Additional Reported Applications For Relevant Conjugates:BNIPWB

Bevacizumab is a monoclonal antibody that specifically recognizes vascular endothelial growth factor (VEGF). VEGF is a growth factor that participates in angiogenesis, vasculogenesis, and endothelial cell growth. It facilitates endothelial cell proliferation, cell migration, and the permeabilization of blood vessels. In addition, VEGF inhibits apoptosis. Bevacizumab neutralizes the biological activity of VEGF by preventing the interaction of VEGF with its receptors on the surface of endothelial cells, resulting in the regression of tumor vascularization, normalization of remaining tumor vasculature, and inhibition of the formation of new tumor vasculature, thus inhibiting tumor growth.1 Anti-Human VEGF (Bevacizumab) utilizes the same variable regions from the therapeutic antibody Bevacizumab making it ideal for research projects.

Regulatory Status:Research Use Only (RUO). Non-Therapeutic.
Storage and Handling:This biotinylated antibody is stable when stored at 2-8°C.Do not freeze.
Research Area:Biosimilars

Related Products